Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs. Intermittent Ceftazidime-Avibactam in Critically Ill Patients
NCT06939829Phase 4Not yet recruiting
- Sponsor
- Southeast University
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Irreversible Covalent Inhibitors
01
Overview
Phase 4, randomised, open-label trial of ceftazidime + avibactam in Infection (2 arms), sponsored by Southeast University. Primary endpoint: 90-day all cause mortality. Planned start May 2025; status: not yet recruiting.
02
Drugs
ceftazidime + avibactam
03
Conditions
Infection
Beyond the preview
Go deeper on NCT06939829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06939829.